IN2014DN08158A - - Google Patents

Info

Publication number
IN2014DN08158A
IN2014DN08158A IN8158DEN2014A IN2014DN08158A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A IN 8158DEN2014 A IN8158DEN2014 A IN 8158DEN2014A IN 2014DN08158 A IN2014DN08158 A IN 2014DN08158A
Authority
IN
India
Prior art keywords
disclosed
methods
function
specific inhibitor
smad7 expression
Prior art date
Application number
Other languages
English (en)
Inventor
Giovanni Monteleone
Peter Buchwald
Luca Inverardi
Antonello Pileggi
Camillo Ricordi
Alice Tomei
Original Assignee
Nogra Pharma Ltd
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd, Univ Miami filed Critical Nogra Pharma Ltd
Publication of IN2014DN08158A publication Critical patent/IN2014DN08158A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN8158DEN2014 2012-04-18 2013-04-18 IN2014DN08158A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625904P 2012-04-18 2012-04-18
PCT/US2013/037150 WO2013158868A1 (en) 2012-04-18 2013-04-18 Methods of treating diabetes and/or promoting survival of pancreatic islets after transplantation

Publications (1)

Publication Number Publication Date
IN2014DN08158A true IN2014DN08158A (ja) 2015-05-01

Family

ID=48326412

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8158DEN2014 IN2014DN08158A (ja) 2012-04-18 2013-04-18

Country Status (15)

Country Link
US (3) US10081809B2 (ja)
EP (1) EP2839004B1 (ja)
JP (2) JP6348484B2 (ja)
KR (1) KR20150003824A (ja)
CN (2) CN107252492A (ja)
AU (1) AU2013249191B2 (ja)
CA (1) CA2870547A1 (ja)
DK (1) DK2839004T3 (ja)
ES (1) ES2732252T3 (ja)
HK (1) HK1207117A1 (ja)
IN (1) IN2014DN08158A (ja)
MX (1) MX370149B (ja)
NZ (1) NZ630914A (ja)
RU (1) RU2667960C2 (ja)
WO (1) WO2013158868A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
HUE032368T2 (en) 2008-11-13 2017-09-28 Nogra Pharma Ltd Antisense preparations and methods for their preparation and application
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
RU2667960C2 (ru) 2012-04-18 2018-09-25 Ногра Фарма Лимитед Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
EP2940115B1 (en) * 2014-04-30 2018-10-17 The Procter and Gamble Company Cleaning composition
MX2016014624A (es) 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
EP3165593B1 (en) * 2015-10-29 2019-01-23 The Procter and Gamble Company Liquid detergent composition
EP3162878A1 (en) * 2015-10-29 2017-05-03 The Procter and Gamble Company Liquid detergent composition
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
EP3790975A4 (en) * 2018-05-08 2022-10-26 University of Miami MATERIALS AND METHODS FOR DELIVERING THERAPEUTIC NUCLEIC ACIDS TO TISSUE
US11434291B2 (en) 2019-05-14 2022-09-06 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
DK2336317T3 (da) * 2003-06-13 2019-12-16 Alnylam Europe Ag Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
ITRM20030393A1 (it) * 2003-08-11 2005-02-12 Giuliani Spa Uso di oligonucleotidi (odn) antisenso per smad7 per il trattamento delle patologie mediate dal fattore di trascrizione nucleare nf-kb.
GB0326778D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
PL1799269T3 (pl) 2004-09-28 2017-01-31 Quark Pharmaceuticals, Inc. Oligorybonukleotydy i sposoby ich zastosowania do leczenia łysienia, ostrej niewydolności nerek i innych chorób
RU2434942C2 (ru) * 2004-09-28 2011-11-27 Кварк Фармасьютикалс, Инк. Олигорибонуклеотиды и способы их применения для лечения острой почечной недостаточности и других заболеваний
WO2007039151A1 (en) 2005-09-28 2007-04-12 Universität Zürich Blockers of transforming growth factor beta and its receptors for the treatment of infectious diseases
US8022046B2 (en) * 2008-04-18 2011-09-20 Baxter International, Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
HUE032368T2 (en) 2008-11-13 2017-09-28 Nogra Pharma Ltd Antisense preparations and methods for their preparation and application
JP6389122B2 (ja) 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
RU2667960C2 (ru) 2012-04-18 2018-09-25 Ногра Фарма Лимитед Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
ES2673209T3 (es) 2013-03-15 2018-06-20 Nogra Pharma Limited Procedimientos de tratamiento del cáncer colorrectal
MX2016014624A (es) 2014-05-09 2017-05-25 Nogra Pharma Ltd Metodos para el tratamiento de enfermedad inflamatoria del intestino.
JP2017537973A (ja) 2014-10-17 2017-12-21 ノグラ ファーマ リミテッド バイオマーカーレベルを使用してｓｍａｄ７アンチセンスオリゴヌクレオチドを投与するおよびモニタリングするための方法
MA43331A (fr) 2014-10-17 2017-08-23 Nogra Pharma Ltd Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
EP3355896A2 (en) 2015-09-30 2018-08-08 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
US20210207143A1 (en) 2016-02-24 2021-07-08 Nogra Pharma Limited Methods of Treating Celiac Disease Using SMAD7 Inhibition
EP3562943A1 (en) 2016-12-30 2019-11-06 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
MX370149B (es) 2019-12-03
CN104487574A (zh) 2015-04-01
AU2013249191B2 (en) 2019-01-03
RU2667960C2 (ru) 2018-09-25
NZ630914A (en) 2017-01-27
CN104487574B (zh) 2017-07-07
RU2014146170A (ru) 2016-06-10
HK1207117A1 (en) 2016-01-22
KR20150003824A (ko) 2015-01-09
DK2839004T3 (da) 2019-07-01
US10443056B2 (en) 2019-10-15
JP6348484B2 (ja) 2018-06-27
EP2839004B1 (en) 2019-06-12
EP2839004A1 (en) 2015-02-25
JP2018131468A (ja) 2018-08-23
AU2013249191A1 (en) 2014-10-09
JP2015514778A (ja) 2015-05-21
WO2013158868A1 (en) 2013-10-24
US20200239884A1 (en) 2020-07-30
US20190136237A1 (en) 2019-05-09
CA2870547A1 (en) 2013-10-24
CN107252492A (zh) 2017-10-17
US20150315573A1 (en) 2015-11-05
MX2014012650A (es) 2015-04-08
ES2732252T3 (es) 2019-11-21
US10081809B2 (en) 2018-09-25

Similar Documents

Publication Publication Date Title
IN2014DN08158A (ja)
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
UA118328C2 (uk) Спосіб інтегрування екзогенних послідовностей у геном рослинної клітини
MX2015013154A (es) Uso de higado desceluralizado por perfusion para receluralizacion de celulas de islote.
GB0920703D0 (en) Compositions containing satiogens and methods of use
PH12014502588A1 (en) Catechol o-methyltransferase activity inhibiting compounds
PH12014500995A1 (en) Pak inhibitors for the treatment of cell proliferative disorders
IL224451A (en) A method for producing cells that produce a pancreatic hormone
EP2536828A4 (en) METHOD FOR EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS
IN2014DN11201A (ja)
PH12014502513A1 (en) Nampt inhibitors
MX2014013752A (es) Inhibidores de nampt.
IL262554A (en) Methods for Purifying Progenitor Pancreatic Cells Derived from Multipotential Stem Cells and Methods for Growing Them
MX348311B (es) Inhibidores nampt.
HK1218430A1 (zh) 通過將幹細胞移植到膽管壁來治療胰腺和肝臟病症的方法
MX2021000332A (es) Metodos para tratar rechazo mediado por anticuerpos en pacientes de trasplante de organos con inhibidor de c1-esterasa.
UA111475C2 (uk) Способи лікування із застосуванням ліпідних сполук
MX337486B (es) Fibras de degradacion controlada.
EP2635678A4 (en) METHOD FOR EFFICIENT MANUFACTURE OF INDUCED PLURIPOTENTER STEM CELLS
EP2616540A4 (en) METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS
SG11201408717XA (en) Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus
IL213629A0 (en) Apparatus and method for the preservation of pancreatic tissue and islet cells for transplantation
MX2010007945A (es) Preparacion y transplante de celulas de isletas pancreaticas.
MX2015007608A (es) Metodos y composiciones para inhibir cnksr1.
IN2014CN02585A (ja)